Systemic treatment with a formulated miR-34 mimic in an orthotopic Kras-activated mouse model of non-small cell lung cancer (NSCLC) led to a significant decrease in tumor burden with a 60% reduction in tumor area compared to mice treated with a control construct. Here, KRAS is linked to neoplasm.